Matthew Rank is a Rheumatology/Immunology physician. OpenAlex indexes 272 publications with 10,658 citations (h-index 45); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Allergy & Immunology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13400 E Shea Blvd
Scottsdale, AZ 852595452
Telephone
480-301-8000Provider last certified this registry record 26 Nov 2024.
Clinical trials
- A Clinical Trial of Soluble Fiber for Asthma
Sponsor: Phoenix Children's Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI US SERVICES INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
66.8%Leukotriene Receptor Antagonist16.9%Montelukast Sodium100%Part D≥22 patientsCorticosteroid16.1%Arnuity Ellipta40%Fluticasone Propionate24%Breyna18%Budesonide18%Part D<11 patients+ 5 more classes in this area
Dermatology
16.6%Interleukin-4 Receptor alpha Antagonist16.6%Dupixent Pen61%Dupixent Syringe39%Part D<11 patientsMetabolism & gastrointestinal
16.6%Corticosteroid16.6%Prednisone100%Part D≥33 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2013–2020 per NIH RePORTER. The latest:
- Step down of asthma biologics in real-world practice settings
Mayo Clinic Arizona
FY2020$21,370R21HL140287 - Step down of asthma biologics in real-world practice settings
Mayo Clinic Arizona
FY2019$121,287R21HL140287 - Step down of asthma biologics in real-world practice settings
Mayo Clinic Arizona
FY2018$122,903R21HL140287
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inflammation in mice
Journal of Allergy and Clinical Immunology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”